Travere Therapeutics is a biopharmaceutical company headquartered in San Diego, California, focused on identifying, developing, and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Travere’s approach is centered on growth through the advancement of an innovative pipeline of late-stage clinical programs targeting rare diseases with significant unmet needs and sustained by a foundation of commercial products. Travere’s lead asset FILSPARI^® (sparsentan) was granted accelerated approval for the reduction of proteinuria in adults with primary IgAN at risk of rapid disease progression in February 2023. Also, sparsentan has completed a Phase 3 clinical trial in focal segmental glomerulosclerosis (FSGS). IgAN and FSGS are rare kidney disorders that often lead to end-stage kidney disease.

The development pipeline is further supported by pegtibatinase (TVT-058), an investigational, novel, pegylated human enzyme, in a Phase 1/2 Study for the treatment of classical homocystinuria (HCU), a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body. Additionally, early research efforts include partnering with government researchers and patient advocates to identify potential therapeutics for Alagille syndrome (ALGS), a condition with no approved treatment options.

The Company also continues to commercialize a successful portfolio of previously approved assets for rare kidney disorders - Thiola EC^® and Thiola^®.

Travere continues to evaluate potential opportunities to expand our pipeline and approved products through licenses and acquisitions of products in areas that will serve rare patients with serious unmet medical needs, and that we believe offer attractive growth characteristics. Research and development efforts are at the forefront of the Company’s mission to address the unmet needs of patients, and this innovation is supported by reinvesting revenues from the commercialized products. Travere is committed to ensuring broad access, and educational, and diagnostic support for patients.

Travere Therapeutics was founded as Retrophin, Inc. in February 2011 and became public in December 2012. We adopted the name Travere Therapeutics, Inc. on November 16, 2020.

Our fiscal year ends December 31.

Travere Therapeutics is listed on the NASDAQ Global Market with a ticker symbol of TVTX.

Travere Therapeutics is incorporated in Delaware.

Travere Therapeutics’ CUSIP number is 89422G107.

We are located at:
3611 Valley Centre Drive, Ste. 300
San Diego, CA 92130

We currently do not pay a dividend and do not offer a Dividend Reinvestment Plan.

Any investor inquiries regarding the transfer or exchange of Travere shares, lost stock certificates, duplicate mailings, change of name requests, change of ownership requests, or change of address requests should be directed to the Transfer Agent, Equiniti Trust Company, LLC (“EQ”):

EQ
PO Box 500
Newark, NJ 07101

To contact EQ’s Shareholder Services, please dial +1 800-937-5449 (toll-free) or +1 718-921-8124 for assistance Monday through Friday from 8:00 a.m. to 8:00 p.m. Eastern Time.

Website for Shareholder Central: https://equiniti.com/us/ast-access/individuals/

To change your address, please contact the transfer agent.

Travere Therapeutics’ independent auditor is Ernst & Young LLP.

View publications here or at SEC.gov. Also see press releases. 

At Travere, we recognize the importance of ESG. While we have not yet adopted a comprehensive ESG reporting system, we have a number of activities and initiatives that align with ESG goals, including, among others: corporate goals and initiatives in furtherance of an inclusive culture and the attraction and retention of diverse talent, the operation of an internal diversity council, providing comprehensive wellness support for employees, supporting access and education for the rare disease community, and the incorporation of ESG initiatives as part of our overall Enterprise Risk Management program. We encourage you to visit the Who We Are page to learn more about our mission, values, and vision, and the initiatives we are committed to supporting.

Please also visit Travere Therapeutics’ Patient Advocacy page to learn more about our involvement in changing the rare disease healthcare system and building a world where every patient is treated fairly and equally.

If you are a shareholder, investor or research analyst or for any questions not handled by the Transfer Agent, please contact ir@travere.com or +1 888-969-7879.
If you are a member of the media, please contact mediarelations@travere.com or +1 888-969-7879. For additional information you may also visit the Press Releases section of our website.
If you would like to submit business development inquiries, please contact us at partnering@travere.com.
For patient inquiries, please contact the Travere Call Center at +1 877-659-5518 or via e-mail at medinfo@travere.com.
To report suspected adverse reactions, contact Travere Therapeutics at +1 877-659-5518, or contact the FDA at +1 800-FDA-1088 or www.fda.gov/medwatch.
All other inquiries may be submitted via the Contact Us form or by calling +1 888-969-7879.  Any personal information you provide us will be processed according to our Privacy Policies.